Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study will treat follicular lymphoma patients who have not received previous treatment
with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will
receive only R-CVP. The two patient groups will be compared to determine if Zevalin given
after R-CVP therapy provides greater benefits than receiving no additional anti-cancer
therapy after R-CVP.